Apogee Therapeutics (APGE) Interest Coverage Ratio (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Interest Coverage Ratio of 0.31 for Q1 2026, up 99.98% year-over-year from 0.15 in Q1 2025, and up 14.52% quarter-over-quarter from 0.36 in Q4 2025.
Apogee Therapeutics (APGE) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Interest Coverage Ratio for 5 consecutive years, with 0.31 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 99.98% year-over-year to 0.31; the TTM figure through Mar 2026 stood at 1.14 (up 99.98% YoY), while the FY2025 annual figure was 1.32, up 53.65% from the prior year.
- Interest Coverage Ratio climbed to 0.31 in Q1 2026 per APGE's latest filing, from 0.36 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.31 in Q1 2026 and bottomed at 1603.66 in Q1 2025.
- Historically, Interest Coverage Ratio has averaged 262.58 across 5 years, with a median of 1.45 in 2025.
- Annual changes were most pronounced in 2025 — Interest Coverage Ratio plunged 485832.35% — and 2026, when it surged 99.98%.
- Apogee Therapeutics' Interest Coverage Ratio stood at 2.11 in 2022, then soared by 41.64% to 1.23 in 2023, then climbed by 18.99% to 1.0 in 2024, then soared by 63.8% to 0.36 in 2025, then increased by 14.52% to 0.31 in 2026.
- Business Quant data shows APGE's Interest Coverage Ratio at 0.31 in Q1 2026, 0.36 in Q4 2025, and 1.62 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.31 |
| Dec 31, 2025 | -0.36 |
| Sep 30, 2025 | -1.62 |
| Jun 30, 2025 | -1.28 |
| Mar 31, 2025 | -1,603.66 |
| Dec 31, 2024 | -1.00 |
| Sep 30, 2024 | -569.91 |
| Jun 30, 2024 | -950.66 |
| Mar 31, 2024 | -0.33 |
| Dec 31, 2023 | -1.23 |
| Sep 30, 2023 | -18.45 |
| Dec 31, 2022 | -2.11 |